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INTRODUCTION
Schizophrenia is a mental illness that appears
from the adolescent period. Its morbidity rate is
estimated at about 1% of the population with no
interracial differences. It is now characterized as a
illness that progresses repeating the relapse-remission
cycle, and a collapse of personality occurs in severe
cases. It consists of two major symptoms. One is
the “positive symptoms” that express such abnormal
behavior as defined in the following diagnostic
terms: “hallucination,” “delusion,” and “agitation.”
The other is the “negative symptoms” that are classified
using the following diagnostic terms: “blunted affect,”
“emotional withdrawal,” and “apathy.” In addition,
the “positive symptoms”mostly emerge at an acute
phase of the illness, and the “negative symptoms”
generally emerge at its chronic phase (1) . The cause
and pathophysiological basis of schizophrenia are
currently unclear, and various hypotheses about
the cause have been proposed, for example, genetic
disorder, neuro-developmental disorder from infancy,
disorder of glutamatergic neurotransmission, and
dopaminergic neuronal disorder, and so on. However,
there is no hypothesis at present that sufficiently
explains the pathphysiological and neurobiological
basis (2) . Schizophrenic patients are now treated with
typical and atypical antipsychotic agents in clinics,
which have an antagonistic effect at dopamine (DA)
D2 receptors.
Fifty years has passed since the initial report of the
antipsychotic activity of chlorpromazine in 1952. The
cause of schizophrenia still remains unknown but
has been hypothesized to be excessive activity of
dopaminergic neurotransmission, and in the mid
1970s, the “DA hypothesis of schizophrenia” was
proposed (3). Based on this hypothesis, many DA
receptor antagonists were developed. It is generally
known that these so-called typical antipsychotics
are effective against the positive symptoms, but
have weak activity against the negative symptoms.
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In terms of safety, this class of drugs is associated
with extrapyramidal side effects such as akathisia,
dystonia and parkinsonian movement disorders,
as well hyperprolactinemia (4, 5). In the late 1980’s, while
the DA hypothesis itself was being modified (6, 7),
there were additional proposals that other neural
systems such as the serotonergic system and gluta-
matergic system may also be involved in the patho-
genesis of schizophrenia, thus complicating the
hypothesis that schizophrenia is due to abnormalities
in DA neurotransmission (8) . New drugs developed
in the 1990s were clozapine, which established the
concept of atypical antipsychotics, risperidone, which
is a serotonin-dopamine antagonist (SDA) , olanzapine
and quetiapine, and in 2000, ziprasidonewas introduced.
Among the shortcomings of the typical antipsychotics,
these antipsychotics largely solved the problem of
extrapyramidal side effects (8, 9) . However, on the other
hand, the atypical antipsychotics are associated with
problems of weight gain, lipid metabolism abnor-
malities, excessive sedation, and cardiac QT pro-
longation, so that there has existed a need for an-
tipsychotics with better safety and tolerability.
At Otsuka Pharmaceuticals, based on the DA
hypothesis, we have focused on drug discovery for
compoundswith inhibitory activity on the dopaminergic
neurotransmission, which are different from the
traditional agents, and have studied DA autoreceptor
agonists since the 1970s. We have focused on agents
to regulate neurotransmission, which act as agonists
at the presynaptic DA autoreceptor and as antagonists
at the postsynaptic DA D2 receptor, and as a result
developed aripiprazole, which is a DA D2 receptor
partial agonist (10-12). Aripiprazole was approved
by the US FDA in November 2002 for schizophrenia
and in the expanded 25 countries in the Europe by
the European Commission (EC) in June 2004. Ad-
ditionally in September 2004, it received a supplemental
approval for the indication of acute manic episode of
bipolar disorder by FDA. An application for approval
is currently pending in Japan for schizophrenia as an
indication. Aripiprazole is a small molecule with 3, 4-
dihydro-2-(1H)-quinolinone as the backbone (Figure 1)
and has attracted attentionas theworld’s first novel anti-
psychotic that is a DA D2 receptor partial agonist
(13-15). In this review, we discuss the activity of
aripiprazole as a DA D2 receptor partial agonist and
discuss the utility of DA D2 receptor partial agonists
in schizo-phrenia.
DA D2 RECEPTOR PARTIAL AGONIST AC-
TIVITY
Substances that bind specifically to the receptor,
such as neurotransmitter, hormones or centrally
acting drugs are called ligands. The concept of a
partial agonist is not a new concept but has been
in existence for a long time as a concept that explains
the reactions mediated by ligands bound to the
receptor and the receptor. Simply, a DA D2 receptor
partial agonist has affinity toward the DAD2 receptor
and an intrinsic activity that is less than the activity
of the endogenous full agonist DA (that is, it can
bind to the DA D2 receptor and cause a similar set
of reaction but themagnitude of the reaction is smaller
than DA). These effects differ from the traditional
typical and atypical DA D2 receptor antagonists. The
partial agonist activity of aripiprazole at the DA D2
receptor has been demonstrated in the 4 in vitro
and ex vivo studies described below.
1) An in vitro receptor binding studywas conducted
using a Chinese hamster ovary (CHO) cell membrane
expressing the recombinant human DAD2 receptor.
The DA D2 receptor agonist had higher affinity to
the DA D2 receptor in the G-protein-coupled state
when compared to the DAD2 receptor in the G-protein-
uncoupled states (16) . Aripiprazole differs from the
DA D2 receptor antagonist haloperidol and as with
the DA D2 receptor partial agonist terguride, has
about a 2-fold higher affinity to the DA D2 receptor
in the G-protein-coupled state than that in theG-protein-
uncoupled state. In addition, aripiprazole had far
higher affinity to the DAD2 receptor compared to the
endogenous neuro-transmitter DA (Table 1) (10) .
These data suggest that aripiprazole is a DA D2
receptor partial agonist.
2) Studies were conducted in vitro with CHO
cell line expressing the recombinant human DA
D2 receptor (10) and rat primary cultures of anterior
pituitary cells (unpublished). In both studies, the
aripiprazole stimulated the DA D2 receptor and the
maximum stimulatory effect was smaller than the full
agonist DA. In the studies conducted with the CHO
cells expressing the recombinant humanDAD2 receptor,
aripiprazole antagonized the stimulatory effect of DA
to the level of aripiprazole (10) (Figure 2). These data
indicate that the aripiprazole is a partial agonist with
intrinsic activity that is less than the full agonist.Figure 1 Structural formula of aripiprazole
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3) Using the CHOcells expressing the recombinant
human DAD2 receptor, we conducted in vitro studies
on spare receptors. Using the alkylating agent EEDQ
to partially inactivate the DA D2 receptor, at the
concentration of EEDQ that has no effect on the
maximum inhibitory effect on cAMP accumulation
by DA, the maximum inhibitory effect of aripipra-
zole on cAMP accumulation decreased dramati-
cally (10) . These data indicate that spare DA receptors
exist, while such receptors do not exist for aripiprazole.
Thus, aripiprazole can be considered to be DA D2
receptor partial agonist.
4) We studied the effect of aripiprazole ex vivo on
the presynaptic DA D2 autoreceptor, which regulates
the activity of tyrosine hydroxylase, a rate-determining
step inDAbiosynthesis.Because thepresynapticDAD2
autoreceptor has many spare receptors while the
postsynaptic DAD2 receptor has essentially no spare
receptors, a DA D2 receptor partial agonist acts as an
agonist at the presynaptic site but as an antagonist
and not as an agonist at the postsynaptic site
(17,18). In animals treated with reserpine or γ-
butylolactone, aripiprazole, like the DA D2 receptor
partial agonist S-(-)-3-PPP (19) , inhibited the increase
in DA biosynthesis and showed DAD2 autoreceptor
agonist activity (11). These results indicate that
aripiprazole is a DA D2 receptor partial agonist.
REGULATION OF DOPAMINERGIC NEU-
ROTRANSMISSION BY DA D2 RECEPTOR
PARTIAL AGONIST ACTIVITY
The DA D2 receptor partial agonist activity is a
characteristic that is not seen with the existing typical
or atypical antipsychotics, DAD2 receptor antagonists.
In contrast to the DA D2 receptor antagonists that
act generally at the DA D2 receptor regardless of
the activity of the in vivo dopaminergic neurotrans-
mission and inhibit the action of DA at the D2
receptor completely at a high dose, the DA D2
receptor partial agonist acts as an antagonist at the
DA D2 receptor in the state of excessive dopaminergic
neurotransmission, while it acts as an agonist at
the DA D2 receptor in the state of low dopaminergic
neurotransmission (20) . The in vitro and in vivo studies
indicated that the DA D2 receptor partial agonist
aripiprazole acts as a DA D2 receptor antagonist in
the states of the excessive dopaminergic neurotrans-
mission and as a DA D2 receptor agonist in the
state of the low dopaminergic neurotransmission
(Figure 2) (10, 11, 21).
AFFINITY AND EFFECTS AT OTHER RE-
CEPTORS
Table 2 shows the affinity of aripiprazole at various
receptors. Aripiprazole has the highest affinity to
the DA D2 receptor, and also has high affinity to
the DA D3 receptor, and the serotonin 5-HT1A and
5-HT2A receptors. Aripiprazole also acts as a partial
agonist at theD3 receptor(12) and the 5-HT1A receptor(22)
and as an antagonist at the 5-HT2A receptor(23).
Aripiprazole at the serotonin 5-HT2A receptor acts
as a partial agonist with low intrinsic activity (12.7%
of 5-HT), and at the serotonin 5-HT2B receptor acts
as an inverse agonist (12).
Aripiprazole has relatively high affinity to the
serotonin 5-HT2A receptor (Ki value : 3.4 nM), but
Table 1 Affinity of antipsychotics to dopamine D2L receptor in the G-protein-coupled or uncoupled state
Drug
Ki value (nM)
[125I]-7-OH-PIPAT
(A)
[3H]-Spiperone
(B)
Ki (B) / Ki (A)
Agonist
Quinpirole
Dopamine
9.5 ± 1.5
17 ± 1.0
634 ± 151
576 ± 192
67
34
Partial agonist
S-(-)-3-PPP
Terguride
Aripiprazole
56 ± 4.5
0.16 ± 0.01
0.34 ± 0.02
1034 ± 231
0.36 ± 0.04
0.70 ± 0.22
18
2
2
Antagonist
Butaclamol
Haloperidol
0.43 ± 0.09
0.30 ± 0.06
0.16 ± 0.01
0.16 ± 0.02
0.4
0.5
n=2 to 4. The data shown is a mean ± SE of n=3 or 4, or in the case of n=2, then the mean of ± 1/2 range. [125I]-7-OH-PIPAT
binding was measured for dopamine D2L receptor in the G-protein-coupled state, while [3H]-spiperone binding was measured for
dopamine D2L receptor in the G-protein-uncoupled state. (Reference 2)
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its affinity to the DA D2 receptor is 10-fold higher
(Ki value : 0.34 nM). The SDA-type antipsychotics
have a relatively higher affinity to the 5-HT2A receptor
than to the D2 receptor, and it has been hypothe-
sized that this is a requirement for clinical utility
as an atypical agent (8) . According to this hypothesis,
aripiprazole would not be an SDA-type agent. As
far as we are aware, there have been 3 reports
from different research institutions on the effect of
aripiprazole on intracerebral DA release in the rat
brain using the intracerebral microdialysis method.
There are 2 reports involving the medial prefrontal
cortex. One study reported that aripiprazole had no
effect onDArelease (24) . In theother study, aripiprazole
promoted DA release in the medial prefrontal
cortex, but the DA release promoting effect was
seen only at the intermediate dose among the 4
doses selected. The effect was mild and without
dose-dependence (25) . There is also 1 report on the
frontal cortex ; aripiprazole had a mild but dose-
dependent effect of decreasing the DA release (26).
There are 2 reports on the striatal system ; in one
report aripiprazole had no effect on DA release (24),
while in the other there was a slight dose-dependent
inhibition of the DA release (26) . These data indicate
that aripiprazole differs not only from the SDA-
type antipsychotics but also the conventional anti-
psychotics in that it has essentially no effect of
promoting DA release from presynaptic sites. The
lack of promotion of DA release by aripiprazole is
postulated to be due to the presynaptic DA D2 recep-
tor autoreceptor agonist activity based on the DA D2
receptor partial agonist activity.
Aripiprazole has low affinity to the adrenergic α1
receptor involved in sedation and orthostatic hypoten-
sion and histamine H1 receptor involved in sedation
and weight gain, and extremely low affinity to the
muscarinic receptor involved in anti-cholinergic
side effects (visual disturbance, thirst, constipation,
urination disorder, and cognitive disorder) (Table 2).
5UTILITYOFARIPIPRAZOLE INTHETREAT-
MENT OF SCHIZOPHRENIA
In short-term placebo-controlled studies conducted
overseas (27-29), aripiprazole improved positive and
negative symptoms in patients with acute exacerbation,
and prevented relapse in a 26-week long-term placebo-
controlled study (30). In a 52-week long-termstudy (31) ,
its improvement in positive symptomswas equivalent
to haloperidol andwas better against negative symptoms
and depressive symptoms. It had a low incidence of
extrapyramidal effects and was shown to have little
effects on the blood prolactin level and weight gain,
which have been seen with other agents (13, 14,
Figure 2 Agonist and antagonist activities of aripiprazole at the dopamine D2 receptor using cAMP accumulation after forskolin
stimulation as an index
In the presence of 10 μM EEDQ, Chinese hamster ovary cells expressing the human dopamine D2L receptor were incubated to
partially inactivate the dopamine D2 receptor. After removing the EEDQ by washing, the effect of aripiprazole on forskolin-
induced cAMP accumulation was measured in the absence (■) and presence (▲) of dopamine at 100 nM. The data shown is the
mean ± 1/2 range of 2 experiments. (Reference 2)
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32-35).
A hypothesis based on the pathophysiological
research has suggested that the mesolimbic dopa-
minergic neurotransmission is in a hyperactivated
state in schizophrenic patients (4-6) . Antipsychotics
have the DAD2 receptor antagonist effect and improve
positive symptoms by inhibiting the postsynaptic
DA D2 receptor in the mesolimbic dopaminergic
neurons and at the same time have extrapyramidal
side effects and hyperprolactinemia by inhibiting
the postsynaptic DA D2 receptor in the substantia
nigra and tuberoinfundibular dopaminergic neurons
respectively (4, 5) . In schizophrenia, the mesolimbic
dopaminergic neurotransmission is in a hyperactive
state, while the tuberoinfundibular dopaminergic
neurotransmission is in normal state and substantia
nigra dopaminergic neurotransmission is actually
in a suppressedstate (6) . In addition, it hasbeen reported
that postsynaptic DA D2 receptors (D2 receptor on
the prolactin-secreting cells in the anterior pituitary)
on the tuberoinfundibular dopaminergic neurons
have spare receptors (36) . Aripiprazole acts as an
antagonist on the mesolimbic postsynaptic DA D2
receptor and thus improves the positive symptoms
by inhibiting the excessive dopaminergic neuro-
transmission. At the same time, it does not
completely inhibit the neurotransmission at the
postsynaptic DA D2 receptor in the substantia nigra
and also has no inhibitory effect at the postsynaptic
DA D2 receptor in the tuberoinfundibular system,
so that there are less extrapyramidal side effects
and no hyperproalctinemia. In schizophrenia, it is
thought that the decreased dopaminergic neuro-
transmission in the prefrontal cortex leads to the
expression of negative symptoms (6,7) , and aripiprazole
has agonist activity at the postsynaptic DA D2
receptor in the prefrontal cortex in the state of low
dopaminergic neurotransmission and improve the
negative symptoms by improving the low neuro-
transmission.
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